XLE Hits 52-Week High as Health Care ETF Bleeds 1%
XLE touched a 52-week high of $67.25 on Oct. 13 with a 50.56% YTD return, while XLV dropped 1.07% as Johnson & Johnson dragged healthcare lower.
Key Points
- XLE closed at $67.20 on October 13, touching a 52-week high of $67.25 on 27.5 million shares, with a YTD total return of 50.56% — the strongest performance of any SPDR sector ETF this year.
- XLV fell 1.07% Wednesday morning, driven by Johnson & Johnson's approximately 5.3% drop on a talc litigation charge and a medical-device revenue miss that dragged pharmaceuticals down 2.98%.
- Traders should watch this week's CPI and PPI releases, which historically accelerate sector ETF rotation and could either extend XLE's run or compress it if a soft inflation print weakens the energy-as-inflation-hedge thesis.
XLE touched a 52-week high of $67.25 on October 13 and closed at $67.20, posting a 50.56% YTD total return on volume of 27.5 million shares — while XLV was losing 1.07% Wednesday morning on a single company's legal bill. The S&P 500 closed flat at 7,805.45, down 0.02%, which means the index number told traders almost nothing about where the real action was.
Energy's Extraordinary Run
Fifty percent in less than ten months is not a sector ETF performance — it is a commodity supercycle trade wearing an equity wrapper. XLE's YTD total return of 50.56% through October 13 has been driven by a confluence of supply discipline from OPEC-plus members, persistent demand from emerging market industrialization, and the re-rating of U.S. energy majors as capital-return machines rather than cyclical extraction businesses. The fund's top holdings — ExxonMobil and Chevron collectively represent more than 40% of XLE's weight — have spent 2026 buying back stock and raising dividends at a pace that would have seemed implausible in the 2020 drawdown.
The October 13 session added 1.80% to a fund that had already run hard, on volume that was above its 30-day average. When a sector ETF hits a 52-week high on elevated volume, the technical read is straightforward: there is no overhead supply, and momentum investors who track relative strength are getting buy signals simultaneously. That creates a self-reinforcing dynamic in the short term. The more relevant question is what stops it. Energy sector ETFs are historically the most sensitive of the 11 SPDR sectors to a sudden demand shock — a Chinese manufacturing slowdown, a sharp dollar spike, or a surprise inventory build can reverse weeks of gains in 48 hours.
This week's sector flow data from Seeking Alpha's weekly ETF tracker showed XLE pulling in $737.06 million in net inflows for the week ended October 9, second only to XLK's $1.5 billion. That is not follow-the-momentum money; $737 million in weekly ETF inflows into a sector requires institutional conviction. The flow size suggests portfolio managers are adding energy as a deliberate allocation, not chasing a chart. Separately, XLC — Communication Services — attracted $667.35 million in weekly inflows, the third-largest sector total, as Meta and Alphabet's advertising revenue recovery continues to drive earnings revisions higher.
Health Care's Company-Specific Catastrophe
XLV's 1.07% decline Wednesday morning is misleading in the best possible way for sector analysts: it looks like a sector move, but it is almost entirely one stock. Johnson & Johnson fell approximately 5.3% after disclosing a fresh talc litigation charge and reporting a medical-device revenue miss that undershot analyst expectations. J&J carries a weight of roughly 9% in XLV, which means a 5.3% drop in that single name mechanically costs the ETF about 48 basis points before any other constituent moves. The additional 59 basis points of decline came from sympathetic selling in pharmaceuticals broadly — the pharmaceuticals sub-sector fell 2.98% — as traders unwound positions in other large-cap health care names on concern that the J&J device miss signals broader procedure-volume weakness.
Biotech compounded the damage, falling 3.04% on the session. That decline had a separate driver: the memory chip selloff, which is now in its sixth consecutive session and has begun bleeding into growth-oriented healthcare names that trade on long-duration cash flow assumptions. When the discount rate implicit in biotech valuations rises — as it does when semis and high-duration tech sell off — biotech ETFs frequently follow, even absent company-specific news. The memory index fell 3.44% on Chinese competition concerns, a theme that has been building since Q2 and shows no near-term catalyst for reversal.
The net effect is that XLV is one of two sector ETFs trading in negative territory with a decline of more than 1% as of Wednesday's mid-morning session, alongside XLI's 0.98% drop. Industrials are being pressured by rising input costs and shipping disruption signals. According to Benzinga's sector ETF coverage, the gap between the day's best and worst sector performers — XLE at plus 1.26% and XLV at minus 1.07% — represents a 233-basis-point spread, which is unusually wide for a session where the benchmark index barely moved.
What Traders Watch Next
The macro event that matters most for sector positioning is arriving this week: CPI and PPI data. Energy ETFs have a well-documented relationship with inflation prints — hot inflation data drives XLE higher because oil and gas prices are both a component of CPI and a hedge against further inflationary pressure. A CPI print above 2.6% consensus would likely push XLE toward a test of $68-$69, an extension of the 52-week high with no technical resistance in sight. The same print would be ambiguous for XLV: higher rates extend the discount on long-duration pharmaceutical pipelines, but health care is also a defensive sector that attracts inflows during risk-off episodes triggered by macro surprises.
For XLV specifically, the J&J situation is not resolved with a single bad session. Talc litigation has been the company's longest-running legal overhang, and new charges signal that the liability tail is longer than the market had priced. Investors who hold XLV as a defensive allocation need to decide whether J&J's 9% weight represents acceptable concentration risk while the litigation plays out. Trimming XLV in favor of a healthcare ETF that underweights J&J — or rotating toward a pharma-specific product with different constituent weights — is the tactical adjustment to evaluate before the next J&J court calendar date.
The level to hold for XLE is $65.00. That mark corresponds to prior consolidation support from August and functions as the line that separates a healthy pullback from the 52-week run from a failed breakout. If CPI comes in soft, risk assets rally, dollar strengthens modestly, and crude gives back $2-3 per barrel, XLE could revisit $65 quickly despite its momentum. The YTD return still looks extraordinary from any angle, but 50% runs in sector ETFs tend to end with sharp corrections when the macro trigger finally flips — and this week's data could be it, or could extend the run by another month. Position sizing, not conviction, is what manages that outcome.
The Weekly Investor
Daily market analysis for active traders. Free.
